Multi-center (mono-vendor) longitudinal conventional and quantitative spinal cord MRI in Multiple Sclerosis at 3 Tesla - The EMISEP Study: First results

Elise Bannier, Benoit Combès, Anne Kerbrat

To cite this version:

HAL Id: inserm-01994583
https://www.hal.inserm.fr/inserm-01994583
Submitted on 25 Jan 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
The EMISEP Study : First results

Multi-center (mono-vendor) longitudinal conventional and quantitative spinal cord MRI in Multiple Sclerosis at 3 Tesla

Funding : French Ministry of Health 2012
Elise Bannier - elise.bannier@irisa.fr
CHU Rennes, Unité/Projet Visages
team.irisa.fr/visages/emisep
Multiple sclerosis (MS) is an often disabling disease of the central nervous system affecting the brain and the spinal cord.

Especially, walking impairment is considered by the patients as the main cause of disability (Hobart et al., 2003).

However, there is a huge heterogeneity in disability progression between patients.

There is a need to identify prognostic factors at the individual level to guide therapeutic decisions.

« Clinico-Radiological paradox »

Barkhof et al. 1999
Can spinal cord involvement more directly explain motor and sensitive impairment and predict disease evolution?

> 75% of spinal cord images show lesions, more frequently in the cervical than thoracic cord (Ikuta et al. 1976, Nijeholt et al. 1998, Bot et al. 2002, Eden et al. 2018)
Correlation with impairment

- Weak: Focal lesions (Kidd et al. 1993, Nijeholt et al. 1998)
- Stronger with quantitative imaging
  - Atrophy (Daams et al. 2014, Kearney et al. 2014)
  - Diffusion and MT imaging (Zackowski et al. 2009, Oh et al. 2013)

Prognosis

- Spinal cord focal lesions have an impact on patient prognosis (Brownlee et al. 2016, Arrambide et al. 2018)
- No long term quantitative studies

Relies on improved image quality for lesion and quantitative imaging (Wheeler-Kingshott 2014, Stroman 2014)
MRI and Multiple Sclerosis – Study design

**EMISEP**

- **Funding:** Ministry of Health 2012
- **Led by Rennes Clinical Trials NCT021173375**
- **PI:** Pr. Gilles Edan / Dr. Anne Kerbrat
- **80 patients - 5-year Brain and Spinal Cord MRI and clinical follow up**
- **3T Research MR scanners**

13 centers initially
3 scanner change
<1 inclusion (2 GE scanners)
→ **7 centers included patients**
5 Siemens, 1 Philips scanner

+ Healthy controls – M0 and M24
EMISEP

Inclusion criteria
RRMS (MacDonald 2010)
First symptoms < 1 year
Brain T2 > 9 and/or SC lesion
EDSS < 3
18 - 45 years old

Clinical follow up
EDSS, 6min, 8 meter, 9 holes peg test
Auto questionnaires MSWS12, Qualiveen
Quantitative : Strength and vibration

MRI and Multiple Sclerosis – What about Spinal Cord MRI?

Imaging protocol

• Whole cord
  - Sag T2 TSE and PSIR TSE
• Cervical cord
  - Axial 2D T2* ME GRE C1-C3 and C4-C7 \(\rightarrow\) lesion
  - Sag 3D T1 \(\rightarrow\) atrophy
  - Ax 3D GRE with and without MT \(\rightarrow\) MTR
  - Sag 30 dir Diffusion
• Brain (OFSEP French MS Cohort protocol)
  - Sag 3D T1 pre Gd
  - Sag 3D FLAIR
  - Ax DP/T2 or 3D T2
  - Ax 30 Dir Diffusion
  - Sag 3D T1 post Gd
81 patients were included between 2014 and 2017
46 healthy controls
to date >18 months follow-up
MRI and Multiple Sclerosis – First results

Magnetization Transfer Ratio

Healthy Controls reproductibility study
  Intra-subject
  Between-subject
  Between-scanner

Patient study at M0

Diffusion imaging

Distortion correction (Snoussi, ISBI 2019)
Lesion location (Chouteau, ECTRIMS 2018)

Lesion imaging

PSIR vs T2 TSE (Rojat et al, JFR 2018)
Article 1

Measurement of Magnetization Transfer Ratio (MTR) from Cervical Spinal Cord: Multicenter Reproducibility and Variability

Combes, Monteau, JMRI 2018
MTR from Cervical Spinal Cord: Multicenter Reproducibility and Variability

<table>
<thead>
<tr>
<th></th>
<th>IRM 1 (Siemens Verio)</th>
<th>IRM 2 (Siemens Verio)</th>
<th>IRM 3 (Siemens Verio)</th>
<th>IRM 4 (Siemens Skyra)</th>
<th>IRM 5 (Siemens Prisma)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td># subjects</td>
<td>4</td>
<td>20</td>
<td>5</td>
<td>5</td>
<td>20</td>
<td>44</td>
</tr>
<tr>
<td># scans</td>
<td>4</td>
<td>20</td>
<td>5</td>
<td>5</td>
<td>30</td>
<td>64</td>
</tr>
</tbody>
</table>

Between scanner
Between session
**Imaging details**

3D GRE, 52 3mm slabs, 0.7mmx0.7mm in-plane resolution, TR/TE=38/3.57ms, 23°, water excitation and GRAPPA 2

MT0 : no prepulse
MT1 : with vendor MT prepulse (Gaussian, 1200Hz off-resonance)

**Processing (Benoît Combès, Post-Doc)**

Registration of MT1 to MT0 using the Anima toolbox (v2.3)*
MTR map computation
Whole cord segmentation
Vertebra labeling
Atlas registration
GW/WM segmentation (>0.8)

*https://github.com/Inria-Visages/Anima-Public/wiki/ , ** De Leener, Neuroimage 2017
MTR from Cervical Spinal Cord: Multicenter Reproducibility and Variability

1. Overall multi-scanner variability
   - Between-scanner variability
   - Between-session variability (same participant, same scanner)
   - Between-participant variability

2. Inter-scanner variability (different scanners, same participant)
   - Inter-participant variability (different participants, same scanner)

Investigated variability
Measured variability
Inhomogeneous MTR values along the cord (C4-C6 plateau)

Between-scanner and between-subject variability overlap
Boxplots of mean MTR measurements in gray matter (GM) and white matter (WM) for each level between C1 and C7 and for C4-C6.
Variation coefficient = \frac{\text{standard deviation}}{\text{mean}} \times 100
Global variation coefficient of 3% (0.9 pu) is compatible with the detection of 1pu MTR Variations between 2 groups (45 per group, type I error= 0.05 and type II error= 0.10)

These results show that it is possible to use cervical cord MTR in multicenter studies

Yet

This was evaluated on a single vendor
Inhomogenous MTR along the cord
The investigation in longitudinal studies remains challenging
Article 2

Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetization transfer ratio study

Combes, Kerbrat, Multiple Sclerosis Journal 2018
Goals

Quantify MTR changes in early RRMS patients in comparison with healthy controls
Describe spatial distribution within and outside lesions
Correlate MTR measurements with clinical scores
MRI and Multiple Sclerosis – First results

MTR from Cervical Spinal Cord: Patient vs Controls at M0

Participants
- 60 RRMS patients
- 34 controls
- Five 3T scanners (same manufacturer)

MRI acquisition
- Lesion imaging (patients)
  - Sag PSIR
  - Sag T2
  - Axial T2*
- MT imaging
  - MT1
  - MT0
- Morphological imaging
  - 3DT1

Image processing
- Lesion mask
- MTR maps
- SC segmentation and vertebral labelling
- Cross-sectional area measurement

Results
- T2 lesion load
- Lesion MTR
- Normal appearing SC MTR
- Whole SC MTR
- Mean cross-sectional area

Mean value for:
- C4-C6 (most reproducible levels)
- Cl, i=1,...,7
- At different distances from cord periphery and barycentre
MTR (C4-C6) is significantly lower in patients versus controls considering the normal appearing spinal cord (lesion excluded) and the whole spine.
MRI and Multiple Sclerosis – First results

MTR from Cervical Spinal Cord: Patient vs Controls at M0

The more focal lesions the lower the MTR, also in the normal appearing spinal cord.

- no lesion
- 1-2 lesions
- 3 lesions or more
MTR from Cervical Spinal Cord: Patient vs Controls at M0

In the sagittal plane

A

B

C

Patient-to-control MTR difference (pu)

Vertebral level

NASC
WC

Mean lesion fraction

0.00
0.02
0.04
0.06

C1 C2 C3 C4 C5 C6 C7
MTR from Cervical Spinal Cord: Patient vs Controls at M0

In the axial plane

(Pardini et al. 2016)
## MTR from Cervical Spinal Cord: Patient vs Controls at M0

### Correlation with clinical scores

<table>
<thead>
<tr>
<th></th>
<th>EDSS</th>
<th>Pyramidal EDSS</th>
<th>8m</th>
<th>6 minutes</th>
<th>12 MSWS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MTR</strong></td>
<td>-0.21</td>
<td><strong>-0.27</strong></td>
<td>-0.08</td>
<td>0.13</td>
<td>-0.12</td>
</tr>
<tr>
<td></td>
<td>(p = 0.14)</td>
<td><strong>(p = 0.05)</strong></td>
<td>(p = 0.57)</td>
<td>(p = 0.36)</td>
<td>(p = 0.39)</td>
</tr>
<tr>
<td><strong>Cord Lesion volume</strong></td>
<td>0.26</td>
<td>0.28</td>
<td>0.00</td>
<td><strong>-0.26</strong></td>
<td><strong>0.30</strong></td>
</tr>
<tr>
<td></td>
<td>(p = 0.06)</td>
<td><strong>(p = 0.03)</strong></td>
<td>(p = 1.00)</td>
<td>(p = 0.05)</td>
<td><strong>(p = 0.03)</strong></td>
</tr>
<tr>
<td><strong>CSA</strong></td>
<td>0.08</td>
<td>0.01</td>
<td>0.04</td>
<td>-0.04</td>
<td>-0.06</td>
</tr>
<tr>
<td></td>
<td>(p = 0.58)</td>
<td>(p = 0.92)</td>
<td>(p = 0.75)</td>
<td>(p = 0.79)</td>
<td>(p = 0.67)</td>
</tr>
<tr>
<td><strong>Brain lesion volume</strong></td>
<td>0.15</td>
<td>0.12</td>
<td>-0.12</td>
<td>-0.11</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td>(p = 0.27)</td>
<td>(p = 0.38)</td>
<td>(p = 0.37)</td>
<td>(p = 0.43)</td>
<td>(p = 0.63)</td>
</tr>
</tbody>
</table>
Diffuse and focal spinal cord burden can be measured at the beginning of the disease, and is correlated with lesion load

Longitudinal data needs to be processed to investigate whether initial burden can predict disability at 1, 2, 3 and 5 years.
A particular case

MTR from Cervical Spinal Cord: Longitudinal data – Ongoing work
### MTR from Cervical Spinal Cord: Longitudinal data

#### A particular case

<table>
<thead>
<tr>
<th>M0</th>
<th>M12</th>
<th>M24</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
</tr>
</tbody>
</table>
Whole cord MTR change between M12 and M0 in a group of 39 patients

...ongoing work
Acknowledgments

- Gilles Edan, Anne Kerbrat and Benoit Combès
- EMISEP study group: Neurologists, radiologists, MR Techs, MR Physicists, Research assistants from Montpellier, Strasbourg, Marseille, Lyon, Clermont-Ferrand, Nîmes and Rennes (list @ team.irisa.fr/visages/emisep)
- Research group Visages (Empenn) Univ Rennes, CNRS, Inria, Inserm, IRISA UMR 6074, Empenn - ERL U 1228
- Ponnada Narayana, Maria Rocca and Denis Ducreux
- Virginie Callot
- Julien Cohen-Adad and his team